Pain control is one of the areas where MDR1 fear does the most damage. Owners hear that some opioids are risky and conclude that their dog must simply tough it out. That is the wrong conclusion. Most of the best pain drugs in veterinary medicine are perfectly safe for MDR1 dogs, and untreated pain is its own serious welfare problem. This guide is about controlling pain after surgery and in chronic conditions — distinct from the pre-surgical sedation question covered in our sedation and anesthesia overview.
First Principle: Most Pain Drugs Are Not P-gp Substrates
The reason a drug is dangerous in an MDR1 dog is that P-glycoprotein normally pumps it out of the brain. The good news for pain management is that the workhorse anti-inflammatory drugs are not meaningful P-glycoprotein substrates. That means the foundation of canine pain control — NSAIDs — is largely safe ground for herding breeds.
So the strategy is not “avoid pain drugs.” It is “build the plan on the safe drugs, and question the one or two that are genuinely P-gp substrates.”
NSAIDs: The Safe Foundation
Veterinary NSAIDs are the backbone of both post-operative and chronic (arthritis) pain control, and they are not P-glycoprotein substrates in a clinically significant way.
- Carprofen (Rimadyl) — the most widely used canine NSAID; considered a safe choice for MDR1 dogs at standard doses.
- Meloxicam, deracoxib, firocoxib (Previcox), robenacoxib — all in the same safe category from an MDR1 standpoint.
The cautions for these drugs are the normal NSAID cautions that apply to every dog, not MDR1-specific ones: they require healthy kidneys and liver, must never be combined with steroids or with another NSAID, and need a baseline blood panel before long-term use. An MDR1 dog on carprofen is being managed for the same reasons as any other dog — the mutation does not add risk here.
The Butorphanol Trap
Butorphanol is the opioid MDR1 owners most need to understand, for two separate reasons.
The first reason is MDR1-specific: butorphanol is a P-glycoprotein substrate, so affected dogs reach higher brain concentrations at a given dose. A 2025 Collie case report documented an exaggerated adverse reaction consistent with this mechanism, reinforcing what pharmacologists already advise — that the dose be reduced for MDR1 dogs.
The second reason has nothing to do with MDR1 at all: butorphanol is a weak, short-acting analgesic. It is a kappa-opioid agonist and mu-antagonist, which makes it useful for mild sedation and cough suppression but a poor choice for real surgical or chronic pain. It often wears off in an hour or two and does not touch significant pain.
Put those two facts together and the conclusion is simple. For a herding breed you have a drug that is both riskier and less effective than the alternatives. That is the trap: it gets reached for out of habit when better options exist. If your dog is sent home after surgery on butorphanol for pain, that is the moment to ask whether a stronger, safer plan is appropriate.
Where Tramadol Fits
Tramadol is commonly prescribed for canine pain, often for chronic or breakthrough pain. The honest picture is mixed. Research has cast doubt on how effective tramadol actually is for pain in dogs, because dogs convert relatively little of it into the active metabolite that provides opioid relief. From an MDR1 standpoint it is not the primary concern that butorphanol is, but its real-world pain benefit is modest.
The practical takeaway: tramadol can be part of a multi-modal plan, but it should not be the sole pillar of pain control for a painful condition. If it is the only thing prescribed and your dog still seems uncomfortable, that is worth raising.
The Uncertain Opioids: Morphine, Fentanyl, Buprenorphine
For the stronger mu-opioids used in serious pain — morphine, fentanyl, and buprenorphine — the MDR1 evidence is less defined rather than clearly dangerous. These drugs are not flagged the way loperamide is, but careful clinicians still favor a cautious, titrated approach in affected dogs: start at the low end, monitor sedation and respiration closely, and adjust to effect.
This is exactly the kind of “use with monitoring” situation where the genotype belongs in the conversation. A dog with severe surgical pain should not be denied an effective opioid; it should receive one under closer observation. Specialty and emergency hospitals manage this routinely.
Building a Safe Pain Plan
A sound approach for an MDR1 dog facing surgery or chronic pain looks like this:
- Anchor on a safe NSAID (carprofen, meloxicam, or similar) when kidney and liver values allow.
- Add multi-modal, non-P-gp tools — gabapentin for nerve-related pain, cold therapy, weight management and joint support for arthritis, and physical rehabilitation.
- Question butorphanol every time it appears, on both safety and effectiveness grounds.
- Reserve the strong opioids for genuine moderate-to-severe pain, given low-and-slow with monitoring.
Questions to Ask Before Any Pain Protocol
Walk into the appointment with three questions. “Is every drug in this plan a P-glycoprotein substrate?” “If butorphanol is included, is there a more effective and safer option?” And “What is the plan if my dog is still painful at home?” For a full script on raising the mutation with your vet, see our talking to your vet about MDR1 guide.
Effective pain relief and MDR1 safety are not in conflict. The mutation rules out a couple of habitual choices and asks for caution with the strongest opioids — but it leaves the entire NSAID-based foundation of modern pain control fully available to your dog.